APO Research
Talk to an analyst

APO RESEARCH · REPORT

RSV Vaccine

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global RSV Vaccine Market Outlook and Growth Opportunities 2026

21 December 2025199 pages

Choose your research edition.

Industry ResearchRSV Vaccine Industry Research Report 2026118 pages · $2,950 USDIndustry Growth & TrendsGlobal RSV Vaccine Industry Growth and Trends Forecast to 203294 pages · $3,450 USDMarket StructureGlobal RSV Vaccine Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032188 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal RSV Vaccine Market Outlook and Growth Opportunities 2026199 pages · $4,250 USDMarket Analysis & ForecastGlobal RSV Vaccine Market Analysis and Forecast 2026-2032197 pages · $4,950 USD

Market perspective

The global RSV Vaccine market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for RSV Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for RSV Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for RSV Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the RSV Vaccine market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the RSV Vaccine market include Nuance Pharma, Pfizer, GSK, Advaccine, Moderna, JNJ and Bavarian Nordic, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global RSV Vaccine market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of RSV Vaccine and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents RSV Vaccine sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the RSV Vaccine market size, projected growth trends, production technologies, key applications, and end-use industries.

RSV Vaccine Segment by Company

Nuance Pharma

Pfizer

GSK

Advaccine

Moderna

JNJ

Bavarian Nordic

RSV Vaccine Segment by Type

Being Developed

Preclinical

Clinical III

Clinical II

Clinical I

RSV Vaccine Segment by Application

Elderly Vaccine

Infant Vaccine

Others

RSV Vaccine Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global RSV Vaccine status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions RSV Vaccine market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify RSV Vaccine significant trends, drivers, influence factors in global and regions.

6. To analyze RSV Vaccine competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global RSV Vaccine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of RSV Vaccine and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of RSV Vaccine.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the RSV Vaccine market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global RSV Vaccine industry.

Chapter 3: Detailed analysis of RSV Vaccine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of RSV Vaccine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of RSV Vaccine in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. RSV Vaccine Industry Trends Table 2. RSV Vaccine Industry Drivers Table 3. RSV Vaccine Industry Opportunities and Challenges Table 4. RSV Vaccine Industry Restraints Table 5. Global RSV Vaccine Revenue by Company (US$ Million) & (2021-2026) Table 6. Global RSV Vaccine Revenue Share by Company (2021-2026) Table 7. Global RSV Vaccine Sales Volume by Company (k units) & (2021-2026) Table 8. Global RSV Vaccine Sales Volume Share by Company (2021-2026) Table 9. Global RSV Vaccine Average Price (US$/unit) of Company (2021-2026) Table 10. Global RSV Vaccine Company Ranking, (2024-2026) & (USD Million) Table 11. Global RSV Vaccine Key Company Manufacturing Base & Headquarters Table 12. Global RSV Vaccine Company, Product Type & Application Table 13. Global RSV Vaccine Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global RSV Vaccine by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Being Developed Table 18. Significant Companies of Preclinical Table 19. Significant Companies of Clinical III Table 20. Significant Companies of Clinical II Table 21. Significant Companies of Clinical I Table 22. Global RSV Vaccine Sales Volume by Type 2021 VS 2025 VS 2032 (k units) Table 23. Global RSV Vaccine Sales Volume by Type (2021-2026) & (k units) Table 24. Global RSV Vaccine Sales Volume by Type (2027-2032) & (k units) Table 25. Global RSV Vaccine Sales Volume Share by Type (2021-2026) Table 26. Global RSV Vaccine Sales Volume Share by Type (2027-2032) Table 27. Global RSV Vaccine Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 28. Global RSV Vaccine Sales Value by Type (2021-2026) & (US$ Million) Table 29. Global RSV Vaccine Sales Value by Type (2027-2032) & (US$ Million) Table 30. Global RSV Vaccine Sales Value Share by Type (2021-2026) Table 31. Global RSV Vaccine Sales Value Share by Type (2027-2032) Table 32. Significant Companies of Elderly Vaccine Table 33. Significant Companies of Infant Vaccine Table 34. Significant Companies of Others Table 35. Global RSV Vaccine Sales Volume by Application 2021 VS 2025 VS 2032 (k units) Table 36. Global RSV Vaccine Sales Volume by Application (2021-2026) & (k units) Table 37. Global RSV Vaccine Sales Volume by Application (2027-2032) & (k units) Table 38. Global RSV Vaccine Sales Volume Share by Application (2021-2026) Table 39. Global RSV Vaccine Sales Volume Share by Application (2027-2032) Table 40. Global RSV Vaccine Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 41. Global RSV Vaccine Sales Value by Application (2021-2026) & (US$ Million) Table 42. Global RSV Vaccine Sales Value by Application (2027-2032) & (US$ Million) Table 43. Global RSV Vaccine Sales Value Share by Application (2021-2026) Table 44. Global RSV Vaccine Sales Value Share by Application (2027-2032) Table 45. Global RSV Vaccine Sales by Region: 2021 VS 2025 VS 2032 (k units) Table 46. Global RSV Vaccine Sales by Region (2021-2026) & (k units) Table 47. Global RSV Vaccine Sales Market Share by Region (2021-2026) Table 48. Global RSV Vaccine Sales by Region (2027-2032) & (k units) Table 49. Global RSV Vaccine Sales Market Share by Region (2027-2032) Table 50. Global RSV Vaccine Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 51. Global RSV Vaccine Sales Value by Region (2021-2026) & (US$ Million) Table 52. Global RSV Vaccine Sales Value Share by Region (2021-2026) Table 53. Global RSV Vaccine Sales Value by Region (2027-2032) & (US$ Million) Table 54. Global RSV Vaccine Sales Value Share by Region (2027-2032) Table 55. Global RSV Vaccine Market Average Price (US$/unit) by Region (2021-2026) Table 56. Global RSV Vaccine Market Average Price (US$/unit) by Region (2027-2032) Table 57. Global RSV Vaccine Sales by Country: 2021 VS 2025 VS 2032 (k units) Table 58. Global RSV Vaccine Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 59. Global RSV Vaccine Sales by Country (2021-2026) & (k units) Table 60. Global RSV Vaccine Sales Market Share by Country (2021-2026) Table 61. Global RSV Vaccine Sales by Country (2027-2032) & (k units) Table 62. Global RSV Vaccine Sales Market Share by Country (2027-2032) Table 63. Global RSV Vaccine Sales Value by Country (2021-2026) & (US$ Million) Table 64. Global RSV Vaccine Sales Value Market Share by Country (2021-2026) Table 65. Global RSV Vaccine Sales Value by Country (2027-2032) & (US$ Million) Table 66. Global RSV Vaccine Sales Value Market Share by Country (2027-2032) Table 67. Nuance Pharma Company Information Table 68. Nuance Pharma Business Overview Table 69. Nuance Pharma RSV Vaccine Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 70. Nuance Pharma RSV Vaccine Product Portfolio Table 71. Nuance Pharma Recent Development Table 72. Pfizer Company Information Table 73. Pfizer Business Overview Table 74. Pfizer RSV Vaccine Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 75. Pfizer RSV Vaccine Product Portfolio Table 76. Pfizer Recent Development Table 77. GSK Company Information Table 78. GSK Business Overview Table 79. GSK RSV Vaccine Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 80. GSK RSV Vaccine Product Portfolio Table 81. GSK Recent Development Table 82. Advaccine Company Information Table 83. Advaccine Business Overview Table 84. Advaccine RSV Vaccine Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 85. Advaccine RSV Vaccine Product Portfolio Table 86. Advaccine Recent Development Table 87. Moderna Company Information Table 88. Moderna Business Overview Table 89. Moderna RSV Vaccine Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 90. Moderna RSV Vaccine Product Portfolio Table 91. Moderna Recent Development Table 92. JNJ Company Information Table 93. JNJ Business Overview Table 94. JNJ RSV Vaccine Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 95. JNJ RSV Vaccine Product Portfolio Table 96. JNJ Recent Development Table 97. Bavarian Nordic Company Information Table 98. Bavarian Nordic Business Overview Table 99. Bavarian Nordic RSV Vaccine Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 100. Bavarian Nordic RSV Vaccine Product Portfolio Table 101. Bavarian Nordic Recent Development Table 102. Key Raw Materials Table 103. Raw Materials Key Suppliers Table 104. RSV Vaccine Distributors List Table 105. RSV Vaccine Customers List Table 106. Research Programs/Design for This Report Table 107. Authors List of This Report Table 108. Secondary Sources Table 109. Primary Sources List of Figures Figure 1. RSV Vaccine Product Image Figure 2. Global RSV Vaccine Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global RSV Vaccine Sales Value (2021-2032) & (US$ Million) Figure 4. Global RSV Vaccine Sales (2021-2032) & (k units) Figure 5. Global RSV Vaccine Sales Average Price (US$/unit) & (2021-2032) Figure 6. Global RSV Vaccine Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Being Developed Image Figure 10. Preclinical Image Figure 11. Clinical III Image Figure 12. Clinical II Image Figure 13. Clinical I Image Figure 14. Global RSV Vaccine Sales Volume by Type (2021 VS 2025 VS 2032) & (k units) Figure 15. Global RSV Vaccine Sales Volume Share 2021 VS 2025 VS 2032 Figure 16. Global RSV Vaccine Sales Volume Share by Type (2021-2032) Figure 17. Global RSV Vaccine Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 18. Global RSV Vaccine Sales Value Share 2021 VS 2025 VS 2032 Figure 19. Global RSV Vaccine Sales Value Share by Type (2021-2032) Figure 20. Elderly Vaccine Image Figure 21. Infant Vaccine Image Figure 22. Others Image Figure 23. Global RSV Vaccine Sales Volume by Application (2021 VS 2025 VS 2032) & (k units) Figure 24. Global RSV Vaccine Sales Volume Share 2021 VS 2025 VS 2032 Figure 25. Global RSV Vaccine Sales Volume Share by Application (2021-2032) Figure 26. Global RSV Vaccine Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 27. Global RSV Vaccine Sales Value Share 2021 VS 2025 VS 2032 Figure 28. Global RSV Vaccine Sales Value Share by Application (2021-2032) Figure 29. Global RSV Vaccine Sales by Region: 2021 VS 2025 VS 2032 (k units) Figure 30. Global RSV Vaccine Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 31. Global RSV Vaccine Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 32. Global RSV Vaccine Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 33. North America RSV Vaccine Sales Value (2021-2032) & (US$ Million) Figure 34. North America RSV Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 35. Europe RSV Vaccine Sales Value (2021-2032) & (US$ Million) Figure 36. Europe RSV Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 37. Asia-Pacific RSV Vaccine Sales Value (2021-2032) & (US$ Million) Figure 38. Asia-Pacific RSV Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 39. South America RSV Vaccine Sales Value (2021-2032) & (US$ Million) Figure 40. South America RSV Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 41. Middle East & Africa RSV Vaccine Sales Value (2021-2032) & (US$ Million) Figure 42. Middle East & Africa RSV Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 43. USA RSV Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. USA RSV Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. USA RSV Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. Canada RSV Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. Canada RSV Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. Canada RSV Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Mexico RSV Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Mexico RSV Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Mexico RSV Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. Germany RSV Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. Germany RSV Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. Germany RSV Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. France RSV Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. France RSV Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. France RSV Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. U.K. RSV Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. U.K. RSV Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. U.K. RSV Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Italy RSV Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Italy RSV Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Italy RSV Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. Spain RSV Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. Spain RSV Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. Spain RSV Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Russia RSV Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Russia RSV Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Russia RSV Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. Netherlands RSV Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. Netherlands RSV Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. Netherlands RSV Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. Nordic Countries RSV Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. Nordic Countries RSV Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. Nordic Countries RSV Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. China RSV Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. China RSV Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. China RSV Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. Japan RSV Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. Japan RSV Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. Japan RSV Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. South Korea RSV Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. South Korea RSV Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. South Korea RSV Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. India RSV Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. India RSV Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. India RSV Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Australia RSV Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Australia RSV Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Australia RSV Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Southeast Asia RSV Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Southeast Asia RSV Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Southeast Asia RSV Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Brazil RSV Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Brazil RSV Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Brazil RSV Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Argentina RSV Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Argentina RSV Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Argentina RSV Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Chile RSV Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Chile RSV Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Chile RSV Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. Colombia RSV Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. Colombia RSV Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. Colombia RSV Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Peru RSV Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Peru RSV Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Peru RSV Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Saudi Arabia RSV Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Saudi Arabia RSV Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Saudi Arabia RSV Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. Israel RSV Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. Israel Arabia RSV Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. Israel Arabia RSV Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. UAE RSV Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 116. UAE RSV Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 117. UAE RSV Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 118. Turkey RSV Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 119. Turkey RSV Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 120. Turkey RSV Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 121. Iran RSV Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 122. Iran RSV Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 123. Iran RSV Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 124. Egypt RSV Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 125. Egypt RSV Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 126. Egypt RSV Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 127. RSV Vaccine Value Chain Figure 128. Manufacturing Cost Structure Figure 129. RSV Vaccine Sales Mode & Process Figure 130. Direct Comparison with Distribution Share Figure 131. Distributors Profiles Figure 132. Years Considered Figure 133. Research Process Figure 134. Key Executives Interviewed

Scope & coverage.

Types
  • Being Developed
  • Preclinical
  • Clinical III
  • Clinical II
  • Clinical I
Applications
  • Elderly Vaccine
  • Infant Vaccine
  • Others
Companies covered
  • Nuance Pharma
  • Pfizer
  • GSK
  • Advaccine
  • Moderna
  • JNJ
  • Bavarian Nordic

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global RSV Vaccine Sales Value (2021-2032)
  4. 1.2.2 Global RSV Vaccine Sales Volume (2021-2032)
  5. 1.2.3 Global RSV Vaccine Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 RSV Vaccine Market Dynamics
  1. 2.1 RSV Vaccine Industry Trends
  2. 2.2 RSV Vaccine Industry Drivers
  3. 2.3 RSV Vaccine Industry Opportunities and Challenges
  4. 2.4 RSV Vaccine Industry Restraints
3 RSV Vaccine Market by Company
  1. 3.1 Global RSV Vaccine Company Revenue Ranking in 2025
  2. 3.2 Global RSV Vaccine Revenue by Company (2021-2026)
  3. 3.3 Global RSV Vaccine Sales Volume by Company (2021-2026)
  4. 3.4 Global RSV Vaccine Average Price by Company (2021-2026)
  5. 3.5 Global RSV Vaccine Company Ranking (2024-2026)
  6. 3.6 Global RSV Vaccine Company Manufacturing Base and Headquarters
  7. 3.7 Global RSV Vaccine Company Product Type and Application
  8. 3.8 Global RSV Vaccine Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global RSV Vaccine Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 RSV Vaccine Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 RSV Vaccine Market by Type
  1. 4.1 RSV Vaccine Type Introduction
  2. 4.1.1 Being Developed
  3. 4.1.2 Preclinical
  4. 4.1.3 Clinical III
  5. 4.1.4 Clinical II
  6. 4.1.5 Clinical I
  7. 4.2 Global RSV Vaccine Sales Volume by Type
  8. 4.2.1 Global RSV Vaccine Sales Volume by Type (2021 VS 2025 VS 2032)
  9. 4.2.2 Global RSV Vaccine Sales Volume by Type (2021-2032)
  10. 4.2.3 Global RSV Vaccine Sales Volume Share by Type (2021-2032)
  11. 4.3 Global RSV Vaccine Sales Value by Type
  12. 4.3.1 Global RSV Vaccine Sales Value by Type (2021 VS 2025 VS 2032)
  13. 4.3.2 Global RSV Vaccine Sales Value by Type (2021-2032)
  14. 4.3.3 Global RSV Vaccine Sales Value Share by Type (2021-2032)
5 RSV Vaccine Market by Application
  1. 5.1 RSV Vaccine Application Introduction
  2. 5.1.1 Elderly Vaccine
  3. 5.1.2 Infant Vaccine
  4. 5.1.3 Others
  5. 5.2 Global RSV Vaccine Sales Volume by Application
  6. 5.2.1 Global RSV Vaccine Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global RSV Vaccine Sales Volume by Application (2021-2032)
  8. 5.2.3 Global RSV Vaccine Sales Volume Share by Application (2021-2032)
  9. 5.3 Global RSV Vaccine Sales Value by Application
  10. 5.3.1 Global RSV Vaccine Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global RSV Vaccine Sales Value by Application (2021-2032)
  12. 5.3.3 Global RSV Vaccine Sales Value Share by Application (2021-2032)
6 RSV Vaccine Regional Sales and Value Analysis
  1. 6.1 Global RSV Vaccine Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global RSV Vaccine Sales by Region (2021-2032)
  3. 6.2.1 Global RSV Vaccine Sales by Region: 2021-2026
  4. 6.2.2 Global RSV Vaccine Sales by Region (2027-2032)
  5. 6.3 Global RSV Vaccine Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global RSV Vaccine Sales Value by Region (2021-2032)
  7. 6.4.1 Global RSV Vaccine Sales Value by Region: 2021-2026
  8. 6.4.2 Global RSV Vaccine Sales Value by Region (2027-2032)
  9. 6.5 Global RSV Vaccine Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America RSV Vaccine Sales Value (2021-2032)
  12. 6.6.2 North America RSV Vaccine Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe RSV Vaccine Sales Value (2021-2032)
  15. 6.7.2 Europe RSV Vaccine Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific RSV Vaccine Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific RSV Vaccine Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America RSV Vaccine Sales Value (2021-2032)
  21. 6.9.2 South America RSV Vaccine Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa RSV Vaccine Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa RSV Vaccine Sales Value Share by Country, 2025 VS 2032
7 RSV Vaccine Country-level Sales and Value Analysis
  1. 7.1 Global RSV Vaccine Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global RSV Vaccine Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global RSV Vaccine Sales by Country (2021-2032)
  4. 7.3.1 Global RSV Vaccine Sales by Country (2021-2026)
  5. 7.3.2 Global RSV Vaccine Sales by Country (2027-2032)
  6. 7.4 Global RSV Vaccine Sales Value by Country (2021-2032)
  7. 7.4.1 Global RSV Vaccine Sales Value by Country (2021-2026)
  8. 7.4.2 Global RSV Vaccine Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA RSV Vaccine Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA RSV Vaccine Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA RSV Vaccine Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada RSV Vaccine Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada RSV Vaccine Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada RSV Vaccine Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico RSV Vaccine Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico RSV Vaccine Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico RSV Vaccine Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany RSV Vaccine Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany RSV Vaccine Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany RSV Vaccine Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France RSV Vaccine Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France RSV Vaccine Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France RSV Vaccine Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. RSV Vaccine Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. RSV Vaccine Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. RSV Vaccine Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy RSV Vaccine Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy RSV Vaccine Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy RSV Vaccine Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain RSV Vaccine Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain RSV Vaccine Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain RSV Vaccine Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia RSV Vaccine Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia RSV Vaccine Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia RSV Vaccine Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands RSV Vaccine Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands RSV Vaccine Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands RSV Vaccine Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries RSV Vaccine Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries RSV Vaccine Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries RSV Vaccine Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China RSV Vaccine Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China RSV Vaccine Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China RSV Vaccine Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan RSV Vaccine Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan RSV Vaccine Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan RSV Vaccine Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea RSV Vaccine Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea RSV Vaccine Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea RSV Vaccine Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India RSV Vaccine Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India RSV Vaccine Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India RSV Vaccine Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia RSV Vaccine Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia RSV Vaccine Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia RSV Vaccine Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia RSV Vaccine Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia RSV Vaccine Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia RSV Vaccine Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil RSV Vaccine Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil RSV Vaccine Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil RSV Vaccine Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina RSV Vaccine Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina RSV Vaccine Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina RSV Vaccine Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile RSV Vaccine Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile RSV Vaccine Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile RSV Vaccine Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia RSV Vaccine Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia RSV Vaccine Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia RSV Vaccine Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru RSV Vaccine Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru RSV Vaccine Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru RSV Vaccine Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia RSV Vaccine Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia RSV Vaccine Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia RSV Vaccine Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel RSV Vaccine Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel RSV Vaccine Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel RSV Vaccine Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE RSV Vaccine Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE RSV Vaccine Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE RSV Vaccine Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey RSV Vaccine Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey RSV Vaccine Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey RSV Vaccine Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran RSV Vaccine Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran RSV Vaccine Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran RSV Vaccine Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt RSV Vaccine Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt RSV Vaccine Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt RSV Vaccine Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Nuance Pharma
  2. 8.1.1 Nuance Pharma Company Information
  3. 8.1.2 Nuance Pharma Business Overview
  4. 8.1.3 Nuance Pharma RSV Vaccine Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Nuance Pharma RSV Vaccine Product Portfolio
  6. 8.1.5 Nuance Pharma Recent Developments
  7. 8.2 Pfizer
  8. 8.2.1 Pfizer Company Information
  9. 8.2.2 Pfizer Business Overview
  10. 8.2.3 Pfizer RSV Vaccine Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Pfizer RSV Vaccine Product Portfolio
  12. 8.2.5 Pfizer Recent Developments
  13. 8.3 GSK
  14. 8.3.1 GSK Company Information
  15. 8.3.2 GSK Business Overview
  16. 8.3.3 GSK RSV Vaccine Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 GSK RSV Vaccine Product Portfolio
  18. 8.3.5 GSK Recent Developments
  19. 8.4 Advaccine
  20. 8.4.1 Advaccine Company Information
  21. 8.4.2 Advaccine Business Overview
  22. 8.4.3 Advaccine RSV Vaccine Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Advaccine RSV Vaccine Product Portfolio
  24. 8.4.5 Advaccine Recent Developments
  25. 8.5 Moderna
  26. 8.5.1 Moderna Company Information
  27. 8.5.2 Moderna Business Overview
  28. 8.5.3 Moderna RSV Vaccine Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Moderna RSV Vaccine Product Portfolio
  30. 8.5.5 Moderna Recent Developments
  31. 8.6 JNJ
  32. 8.6.1 JNJ Company Information
  33. 8.6.2 JNJ Business Overview
  34. 8.6.3 JNJ RSV Vaccine Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 JNJ RSV Vaccine Product Portfolio
  36. 8.6.5 JNJ Recent Developments
  37. 8.7 Bavarian Nordic
  38. 8.7.1 Bavarian Nordic Company Information
  39. 8.7.2 Bavarian Nordic Business Overview
  40. 8.7.3 Bavarian Nordic RSV Vaccine Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Bavarian Nordic RSV Vaccine Product Portfolio
  42. 8.7.5 Bavarian Nordic Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 RSV Vaccine Value Chain Analysis
  2. 9.1.1 RSV Vaccine Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 RSV Vaccine Sales Mode & Process
  6. 9.2 RSV Vaccine Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 RSV Vaccine Distributors
  9. 9.2.3 RSV Vaccine Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst